Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

In this RegMedNet interview, Professor Anna David discusses her Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø TRO supported research involving the development of new treatments for fetal growth restriction using maternal gene therapy.

With fetal growth restriction affecting 8%-10% of pregnancies and being untreatable by available drugs, Professor Anna David and team identified this as a need to try an alternative treatment, which led to them developing gene therapy for mother's to treat fetal disease. 

In this interview, Anna discusses the challenges of administering a fetal gene therapy, her experiences working with UK regulators, and next steps in her research.